Kevin Astle, Pharm.D., discussed on-demand HIV preexposure prophylaxis (PrEP), the advent of long-term injectables, and updated CDC guidelines at the AMCP Nexus 2022 meeting in National Harbor, Maryland.
This interview was recorded prior to the meeting.
When the Centers for Disease Control and Prevention (CDC) updated its guidelines for HIV preexposure prophylaxis (PrEP) late last year, it greatly expanded the number of people eligible for the strategy of taking HIV antiviral therapy to prevent infection, explains Kevin Astle, Pharm.D., an assistant professor at the University of South Florida Health Taneja College of Pharmacy in Tampa, Florida.
In an interview with Managed Healthcare Executive® recorded before his talk at at the AMCP Nexus 2022 meeting in National Harbor, Maryland, Astle noted that previous guidelines focused on men who have sex with men and IV drug users. The newer guidelines expand the PrEP-eligible population to include anyone who has multiple sexual partners in the last six months, he said.
"We're going to see a much larger population of patients eligible for PrEP," said Astle.
Astle also described long-acting injectable HIV PrEP as a "game changer." The FDA approved the Apretude (cabotegravir extended-release injectable suspension) in December 2021.
He also discussed on-demand PrEP, which involves taking two antiviral pills before having sex and then one per pill per day for two days afterward.
How Prime Therapeutics Tugged on the Reins of the Galloping GLP-1 Spend | AMCP Nexus 2023
October 20th 2023The Minnesota-based pharmacy benefit manager says a program that resulted in patients switching from two incretin therapy prescriptions to one yielded $7,500 in savings per patient and a total of $3.5 million.
Read More
Race, Income Impact Specialty Drug Use of Autoimmune Condition Treatments | AMCP Nexus 2023
October 20th 2023In a platinum award winning poster presented at the AMCP Nexus 2023 conference in Orlando, “Specialty drug use varies by race and wage among employees with employer-sponsored health insurance,” authors expressed that spending on specialty medications for autoimmune conditions has increased in recent years, raising affordability concerns for employers.
Read More
The Oncology Pipeline Is Delivering Exciting New Treatments — and Sticker Shock | AMCP Nexus 2023
October 19th 2023Research continues to develop new therapies for rare cancers and to provide options that allow for fewer toxicities. At the same, however, more new drugs are launching with high price tags.
Read More
The Benefits of ML, AI Use in Managed Care Pharmacy | AMCP Nexus 2023
October 19th 2023Adopting evolving computer system tools like artificial intelligence and machine learning in managed care pharmacies have resulted in efficiency when addressing the challenges they are faced with, according to Jessica Hatton, PharmD, BCACP, associate vice president of Pharmacy at CareSource and Nick Trego, PharmD, senior vice president of Clinical Analytics and Client Services at HealthPlan Data Solutions, Inc.
Read More
Outcomes From Horizon BCBS of New Jersey Oncology Home Infusion Program | AMCP Nexus 2023
October 19th 2023The program yielded savings of $25,000 per patient in its pilot phase but is not expected to produce savings as a routine offering because reimbursement for home infusion was matched to reimbursement at a facility. Horizon executive Timothy O’Shea, Pharm.D., M.S., says cost savings were a “secondary outcome” of the program and noted the high patient satisfaction.
Read More